Skip to main content

Advertisement

Table 2 Heart rates of TNBC patients after cycles of chemotherapy

From: The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study

Regimen Time point
Baseline Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7
Overall
 Cases (%) 142 (96.6) 85 (57.8) 90 (61.2) 87 (59.2) 85 (57.8) 73 (49.7) 60 (40.8) 34 (23.1)
 Heart rate (bpm, mean ± SD) 75.3 ± 11.4 79.4 ± 11.8 80.6 ± 12.3 79.8 ± 12.2 79.0 ± 13.4 82.6 ± 12.2 82.7 ± 13.3 80.7 ± 12.0
 P value Ref < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.003
Anthracyclines
 Cases (%) 87 (97.8) 57 (64.0) 58 (65.2) 56 (62.9) 54 (60.7) 45 (50.6) 41 (46.1) 33 (37.1)
 Heart rate (bpm, mean ± SD) 74.8 ± 11.1 79.7 ± 11.7 80.1 ± 11.5 80.5 ± 11.8 79.7 ± 14.9 81.4 ± 11.3 82.7 ± 12.2 80.7 ± 12.1
 P value Ref 0.001 < 0.001 < 0.001 0.008 < 0.001 < 0.001 0.004
Cyclophosphamide
 Cases (%) 80 (98.8) 50 (61.7) 49 (60.5) 49 (60.5) 44 (54.3) 36 (44.4) 39 (48.1) 30 (37.0)
 Heart rate (bpm, mean ± SD) 73.5 ± 11.2 77.4 ± 12.0 78.7 ± 12.7 79.9 ± 13.1 78.2 ± 10.1 78.9 ± 11.8 81.3 ± 13.5 80.2 ± 12.1
 P value Ref 0.004 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.001
Paclitaxel
 Cases (%) 60 (96.8) 37 (59.7) 39 (62.9) 39 (62.9) 43 (69.4) 28 (45.2) 28 (45.2) 18 (29.0)
 Heart rate (bpm, mean ± SD) 74.1 ± 10.0 80.6 ± 12.1 77.8 ± 10.9 79.8 ± 10.5 81.2 ± 9.0 82.0 ± 10.5 84.4 ± 14.2 81.9 ± 12.7
 P value Ref < 0.001 < 0.001 0.002 < 0.001 < 0.001 0.002 0.086
Docetaxel
 Cases (%) 56 (94.9) 35 (59.3) 39 (66.1) 36 (61.0) 34 (57.6) 36 (61.0) 24 (40.7) 14 (23.7)
 Heart rate (bpm, mean ± SD) 76.4 ± 13.2 78.9 ± 12.3 83.3 ± 14.0 80.4 ± 14.9 79.0 ± 12.2 83.4 ± 13.9 80.3 ± 13.5 79.6 ± 12.2
 P value Ref 0.137 0.001 0.037 0.036 0.004 0.231 0.004
Carboplatin
 Cases (%) 40 (93.0) 20 (46.51) 25 (58.1) 23 (53.5) 25 (58.1) 26 (60.5) 14 (32.6) NA
 Heart rate (bpm, mean ± SD) 76.1 ± 11.6 78.3 ± 9.2 81.6 ± 11.3 77.3 ± 9.9 79.0 ± 9.1 85.8 ± 11.9 86.0 ± 14.5 NA
 P value Ref 0.442 0.023 0.690 0.034 0.001 0.157 NA
  1. All data are compared with baseline values. NA, not applicable (platinum-based chemotherapy was used for only 4–6 cycles)